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Should we delay covid-19 vaccination in children?
The net benefit of vaccinating children is unclear, and vulnerable people worldwide should be
prioritised instead, say Dominic Wilkinson, Ilora Finlay, and Andrew J Pollard. But Lisa Forsberg
and Anthony Skelton argue that covid-19 vaccines have been approved for some children and that
children should not be disadvantaged because of policy choices that impede global vaccination
Dominic Wilkinson, 1 , 2 , 3 Ilora Finlay, 4 Andrew J Pollard, 2 , 5 , 6 Lisa Forsberg, 1 , 7 Anthony Skelton8
Yes—Dominic Wilkinson, Ilora Finlay, and
Andrew J Pollard
For a health system to offer any vaccine to a child,
two key ethical questions must be asked. First, do
thebenefits outweigh the risks? Second, if the vaccine
is in short supply, does someone else need it more?
Careful attention to both questions suggests that we
should not yet roll out covid-19 vaccination to
otherwise healthy children.
Covid-19 vaccines in adults have been remarkably
effective. There is good reason to expect that the same
will be true in children. Preliminary studies in
adolescents indicate high levels of antibody
production and 93-100% effectiveness in preventing
covid-19.1 2 This has led to licensing decisions in the
UK, the US, and elsewhere.
Less benefit
In older adults, the benefits of covid vaccines clearly
outweigh the rare side effects. But in children there
are some key differences.
First,we know less about the risks. Randomised trials
to date have given vaccines to only about 3500
adolescents. These trials are not designed to identify
rare side effects.3 For example, the US government’s
Centers for Disease Control and Prevention has
recently identified a risk ofmyocarditis in adolescents
who have received mRNA based covid-19 vaccines
(an estimated 56-69 cases permillion vaccinedoses).4
We do not know whether other complications will
emerge.
Second, the potential benefit in children is much
smaller. Most children who get covid-19 have mild
illness. There are low risks of hospital admission and
death (around two per million children in the UK),
as well as rare multisystem inflammatory
syndrome.5 6 There are also indirect effects (for
example, interrupted education) and potential long
covid. However, serious illness from covid is much
less common than in adults. Moreover, young
children and schools seem to play a limited role in
transmission.7 Vaccination of children would have
marginal benefit in protecting others, particularly
once people at higher risk are immunised.8
Before we roll out a covid-19 vaccine for children, we
should scrutinise safety data carefully and wait if
there is anyuncertainty. Crucially, if reports of serious
complications arise they could harm our wider
immunisation programme. Community confidence
in vaccination can be easily threatened,3 leading to
surges in vaccine preventable disease.9
The difficult question is, do the benefits outweigh
the risks? In children with certain chronic or acute
serious illnesses theyprobably do, and these children
should therefore have access to a vaccine. But in
otherwise healthy children, no one can currently be
sure.
Global inequity
We can be sure of one thing, however. In the UK,
some people are currently at much higher risk from
covid-19 than healthy children. And most lower
income countries have fully vaccinated less than 5%
of their community.10 Nepal, which is facing a severe
surge of the delta variant, suspended its vaccination
programme last month because of a lack of vaccine
supply and infrastructure.11
Some experts have argued that the number of doses
required to vaccinate children in high income
countries is small, but in many countries the entire
at-risk older population could be vaccinated if they
received anumber of doses equivalent to thenumber
of UK schoolchildren.
The UK has committed funds to Covax, a worldwide
initiative aimed at equitable access to covid-19
vaccines directed by Gavi, the Vaccine Alliance, as
well as the Coalition for Epidemic Preparedness
Innovations and the World Health Organization. It
has promised to donate 100 million surplus doses
over the next year, but most doses promised by
wealthy countries will not arrive until the end of 2021
or next year. In the meantime, further variants are
emerging.
Some might ask, why do we have to choose? Can’t
we vaccinate children as well as people overseas?
But, to put it simply, there are right now a limited
number of vaccine doses. As adults, we have had to
wait our turn for the vaccine. We have understood
that, given its scarcity, the vaccine has to be
prioritised for people at the highest risk of dying. This
clear and inescapable ethic now applies to our
children. Their turn will come—but not yet.
No—Lisa Forsberg and Anthony Skelton
TheUKgovernment is decidingwhether to extend its
vaccinationprogramme to childrenaged 12 andolder,
after the Medicines and Healthcare Products
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Regulatory Agency approved the Pfizer-BioNTech vaccine for this
age group.12
We have recently argued in the Conversation, an independent
academic news source, that there are three broad reasons to
vaccinate childrenagainst covid-1913: it protects children themselves
from the risk of harm and death from infection; it protects others;
and it is the bestway to promote children’swellbeing byminimising
the need for restrictions or disruptions to their lives resulting from
failure to properly manage infection spread. Here we respond to
two further arguments for delaying vaccination in children.
Safe and effective
One argument, despite the existence of safe and effective vaccines,
is that the cost-benefit ratio of covid-19 vaccination is less
advantageous for children than for older people. Children are less
likely to be severelyharmedby covid-19 infection, and they therefore
benefit less from a vaccination protecting them from it. Further, the
argument continues, because we have limited knowledge of the
long term effects of covid-19 vaccination in children, we should
delay vaccinating them.
But this argument is mistaken. Medical authorities have judged
covid-19 vaccines to be safe and effective for children, and they
have so far been approved for use in children aged 12 and over. The
European Medicines Agency states that any risks in this age group
are outweighed by the benefits,14 and Health Canada and the US
Centers for Disease Control and Prevention agree.
Millions of children have been vaccinated. Side effects so far are
extremely rare. And, while the immediate severe effects of covid-19
are considerably less common in children than in older adults, a
child has a considerably greater risk of harm fromcovid-19 infection
than from vaccination against it. Children can be severely affected
by covid-19 infection: they may die as a result, or they may develop
long covid or multisystem inflammatory syndrome.15
It is true that we have limited knowledge of the long term effects of
covid-19 vaccination. But vaccines in use are closely monitored,
enabling us to act on any unexpected side effects, as we did with
the AstraZeneca vaccine.
It is also equally true that we have limited knowledge of the long
term effects of covid-19 infection. And in the case of infection, there
has been limited (if any) monitoring of mild and asymptomatic
cases, as these have been thought to be largely unproblematic. But
we now know that people with mild or asymptomatic infection may
nevertheless develop long term health complications.16
Delaying vaccination against covid-19 in children is not, then, the
more risk averse decision. Doing so exposes children to unknown
risks of severe disease and of long term health complications. And,
of course, new variants can occur from permitting extensive
infection spread in young people in rich countries, too.
Moreover, we now know that exposing children to those risks
disproportionately harms already disadvantaged children. The
effects of delaying vaccination are seen in the recent outbreak in
the Kashechewan First Nation in northern Ontario. Despite most
adults in this population already being vaccinated, of the roughly
300 people infected with covid-19 most were aged under 18.17 18
Those who are already disadvantaged are thus exposed to known
and unknown risks of harm.
Pharma profits
A second argument for delaying the vaccination of children is that
priority should be given to older adults in developing countries
where vaccine supply has been limited. A key assumption of this
argument is mistaken.
Global vaccine supply is currently limited, and some countries have
severe shortages. The shortages result from a policy choice.
Governments in rich countries have—even in an
emergency—prioritiseddrug companies’ interests inmaking aprofit
over health and life, despite many governments having invested
considerably in vaccine development at risk and despite much of
the scientific endeavour occurring in publicly funded universities,
such as Oxford.
The ethically defensible choice is to exert whatever pressure we can
tominimise vaccine hoarding anddistribute vaccines to developing
countries, while releasing patents and allowing the manufacture
and supply of vaccines on a larger scale, to enable vaccination of
adults and children everywhere.19 -22
Accepting the “austerity” narrative that children must wait until
the most vulnerable people in other countries can be vaccinated
diverts focus from the real problem: that profits are valued over
lives. We should be calling for change, not accepting manufactured
scarcity as inevitable.
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